Results 201 to 210 of about 38,240 (235)
Some of the next articles are maybe not open access.
Acute Respiratory Failure with a Single Dose of Quetiapine Fumarate
Annals of Pharmacotherapy, 2006Objective: To report a case of acute respiratory failure after a single dose of quetiapine fumarate in an elderly patient with a history of chronic obstructive pulmonary disease (COPD). Case Summary: A 92-year-old woman with a history of COPD was admitted to the hospital with pneumonia. Her symptoms improved with antibiotics. Because of acute agitation
Seema, Jabeen +2 more
openaire +2 more sources
Quetiapine fumarate for schizophrenia and bipolar disorder in young patients
Drugs of Today, 2010During the past decade, there has been a substantial increase in the prescribing of antipsychotics to young patients for a variety of pediatric psychiatric disorders. Quetiapine (Seroquel®) received its initial indication from the U.S. Food and Drug Administration for treatment of schizophrenia in 1997, and it received its second indication for the ...
RIBOLSI, MICHELE +2 more
openaire +4 more sources
Drug Development and Industrial Pharmacy
Background Quetiapine fumarate (QTP) is commonly prescribed for schizophrenic patient, typically available in tablet or oral suspension form, presenting challenges such as administration difficulties, fear of choking and distaste for its bitter taste ...
Hiu Ching Phang +9 more
semanticscholar +1 more source
Background Quetiapine fumarate (QTP) is commonly prescribed for schizophrenic patient, typically available in tablet or oral suspension form, presenting challenges such as administration difficulties, fear of choking and distaste for its bitter taste ...
Hiu Ching Phang +9 more
semanticscholar +1 more source
Identification, isolation, synthesis and characterization of impurities of quetiapine fumarate
Die Pharmazie, 2008In the process for the preparation of quetiapine fumarate (1), six unknown impurities and one known impurity (intermediate) were identified ranging from 0.05-0.15% by reverse-phase HPLC. These impurities were isolated from crude samples using reverse-phase preparative HPLC. Based on the spectral data, the impurities were characterized as 2-[4-dibenzo[b,
Dandala, R. +2 more
openaire +3 more sources
International Clinical Psychopharmacology, 2011
The objective of this study was to evaluate the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) as maintenance monotherapy for patients with generalized anxiety disorder (GAD). Time-to-event (anxiety symptom recurrence; maximum 52 weeks) multicenter, randomized-withdrawal, parallel-group, double-blind, placebo ...
Martin A, Katzman +5 more
openaire +2 more sources
The objective of this study was to evaluate the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) as maintenance monotherapy for patients with generalized anxiety disorder (GAD). Time-to-event (anxiety symptom recurrence; maximum 52 weeks) multicenter, randomized-withdrawal, parallel-group, double-blind, placebo ...
Martin A, Katzman +5 more
openaire +2 more sources
Attentional improvement following quetiapine fumarate treatment in schizophrenia.
Schizophrenia research, 1999This study examined changes in attentional performance in patients with schizophrenia during the 2 months after initiating treatment with quetiapine fumarate. Prior to treatment, attentional performance in patients with schizophrenia (n = 10) was significantly (p < 0.01) worse than in matched controls (n = 12).
K W, Sax, S M, Strakowski, P E, Keck
openaire +1 more source
Extended Release Quetiapine Fumarate Monotherapy in Major Depressive Disorder
The Journal of Clinical Psychiatry, 2009To evaluate the efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) as monotherapy treatment for major depressive disorder (MDD).This 8-week (6-week active-treatment, randomized phase; 2-week posttreatment drug-discontinuation/tapering phase), multicenter, double-blind, randomized, parallel-group, placebo- and ...
Andrew J, Cutler +5 more
openaire +2 more sources
[Early phase II study of quetiapine fumarate on schizophrenia].
Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 1999The efficacy and safety of quetiapine fumurate in the treatment of patients with schizophrenia were evaluated in an 8-week, multicenter, open-label study. The results of this study which included a total of 54 patients showed good efficacy and safety profile for quetiapine fumarate as seen by the improvement rate (moderate or above in the final global ...
M, Murasaki +5 more
openaire +1 more source